These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

861 related items for PubMed ID: 16959680

  • 1. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J.
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [Abstract] [Full Text] [Related]

  • 7. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 8. Development of generic low molecular weight heparins: a perspective.
    Fareed J, Leong W, Hoppensteadt DA, Jeske WP, Walenga J, Bick RL.
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM, Jackson CM, Kessler CM.
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC, Cohen M, Montalescot G.
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
    Xu X, Li D, Chi L, Du X, Bai X, Chi L.
    Carbohydr Res; 2015 Apr 30; 407():26-33. PubMed ID: 25701653
    [Abstract] [Full Text] [Related]

  • 20. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
    Harenberg J.
    Clin Appl Thromb Hemost; 2011 Apr 30; 17(6):E158-64. PubMed ID: 21406409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.